Brookline Capital Markets Estimates CervoMed Q3 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Markets raised their Q3 2026 earnings per share (EPS) estimates for CervoMed in a report released on Tuesday, August 11th. Brookline Capital Markets analyst F. Ahmed now expects that the company will earn ($0.73) per share for the quarter, up from their previous estimate of ($1.04). The consensus estimate for CervoMed’s current full-year earnings is ($2.84) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.97) EPS.

CRVO has been the topic of several other research reports. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price objective on shares of CervoMed in a research note on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating on shares of CervoMed in a report on Wednesday. Chardan Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. Roth Capital set a $9.00 price target on shares of CervoMed in a research note on Monday, May 18th. Finally, Weiss Ratings downgraded shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CervoMed presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

CervoMed Stock Down 0.6%

Shares of NASDAQ CRVO opened at $3.07 on Thursday. The company’s fifty day moving average is $3.12 and its 200-day moving average is $3.77. The stock has a market cap of $46.42 million, a price-to-earnings ratio of -0.95 and a beta of -0.63. CervoMed has a twelve month low of $2.13 and a twelve month high of $11.25.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.22. CervoMed had a negative return on equity of 166.00% and a negative net margin of 672.80%.

Insider Buying and Selling at CervoMed

In other CervoMed news, Director Joshua S. Boger acquired 955,414 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the completion of the acquisition, the director directly owned 1,795,865 shares of the company’s stock, valued at approximately $5,639,016.10. This trade represents a 113.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 35.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CervoMed

Large investors have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after acquiring an additional 1,526 shares in the last quarter. State Street Corp increased its position in shares of CervoMed by 11.4% during the 4th quarter. State Street Corp now owns 20,527 shares of the company’s stock worth $162,000 after purchasing an additional 2,100 shares during the last quarter. Vanguard Group Inc. increased its position in shares of CervoMed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares during the last quarter. Citizens Financial Group Inc. RI raised its stake in shares of CervoMed by 23.0% during the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock worth $296,000 after purchasing an additional 7,000 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of CervoMed during the 4th quarter worth approximately $81,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.